TECH Stock Jumps As Activist Pressure And Bullish Calls Collide

Bio-Techne Corp stocks have been trading up by 19.77 percent following strong demand for its life-science research tools.

Live Update At 11:33:33 EDT: On Thursday, June 25, 2026 Bio-Techne Corp stock [NASDAQ: TECH] is trending up by 19.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TECH has gone from sleepy to explosive in a few sessions. On 2026/06/01, Bio-Techne closed near $50.79. By 2026/06/25, the stock finished around $70.52. That is roughly a 39% surge in less than a month, with an especially sharp spike from $58.88 to over $70 in the latest session.

For active traders, that move screams “re-rating.” The multi-day chart shows TECH grinding higher from the high-$40s, pausing in the low-$50s, then breaking out hard once the $58–$60 band gave way. Intraday, the 5‑minute tape around $70 shows tight ranges and steady bids, not wild wicks. That’s the kind of controlled strength momentum traders look for when funds are accumulating.

More Breaking News

• AMC Stock Slides As Dilutive Offerings Clash With Box Office Rebound
• RIVN Stock Slides As Layoffs, Pricing, And Safety Probe Rattle Traders
• Absci (ABSI) Stock Rallies As Wall Street Boosts Targets
• BMNR Stock Tests Support As BitMine Unveils High-Yield Preferred Deal

Under the hood, TECH is not a cheap name. Bio-Techne trades at about 7.15x sales and a lofty ~79x earnings, with a rich price-to-free-cash ratio near 27. But the company backs that valuation with a 65% gross margin, solid 21.2% EBITDA margin, and low leverage: total debt-to-equity is just 0.14, and the current ratio is a comfortable 4.5. Q3 revenue came in around $311.4M with net income near $51.0M and free cash flow of about $77.6M. For traders, that combination of high quality, strong cash generation, and fresh momentum puts TECH squarely on breakout watch lists.

Why Traders Are Watching TECH Now

The recent ramp in TECH is not happening in a vacuum. It’s being fueled by a cluster of headlines that change how the market frames Bio-Techne’s next few years.

First, the Street tone. TD Cowen just reiterated its Buy rating on Bio-Techne and called TECH one of its top small/mid-cap ideas for 2026, with a $65 price target. That call came after a “modest” year-to-date selloff, suggesting Cowen sees the past weakness as mispricing, not the start of a downtrend. The firm expects improving end markets into fiscal 2027, which gives swing traders a clear time horizon for a potential multi-year uptrend story.

On the flip side, Piper Sandler stepped in with a Neutral rating and a $65 target, then trimmed that target to $60 while staying Neutral. The message is simple: TECH faces macro drag from biotech and academic spending, plus China exposure, so the near-term backdrop is choppy. But even Piper’s initial $65 level sat above the then-Street average of roughly $61.55, and the broader consensus on Bio-Techne remains Overweight with an average target near $61.42. Translation for traders: some caution, yes, but the Street still leans bullish overall.

Then comes the kicker—activism. Ananym Capital Management has taken a stake in Bio-Techne and is pressuring the board to run a strategic review, including a possible sale to a larger industry player. That turns TECH into a potential M&A and event-driven trading vehicle overnight. Activist campaigns often force boards to sharpen execution or explore deals, and either path can trigger strong moves in a stock that screens as “underappreciated,” as TD Cowen argued.

Layer on the Refeyn collaboration, where Bio-Techne and the UK partner launched a first-of-its-kind workflow combining MauriceFlex icIEF fractionation with Refeyn’s mass photometry. This 4‑hour antibody and protein analysis process helps drug makers catch flaws earlier and reduce risk in complex biologics and biosimilars. For traders, that innovation story supports the premium multiple and adds a fundamental tailwind beneath the recent price action.

Conclusion

TECH is now a classic battleground-for-upside setup—exactly the kind of name active traders on timothysykes.com and StocksToTrade pay attention to. Bio-Techne has a rich valuation, but it also has strong margins, solid cash flow, and a clean balance sheet. The stock has ripped from the $50s into the $70 area as traders price in a new narrative: activist pressure, a credible M&A angle, and a Street that still largely believes there is room above current levels.

The TD Cowen call paints TECH as underappreciated heading into 2026 and fiscal 2027, while Piper Sandler’s more cautious stance reminds everyone that macro and China risk are real. That push-pull sets up volatility, which is where disciplined trading shines. The Refeyn partnership adds a longer-term growth plank as Bio-Techne leans into high-value biologics workflows that can deepen customer ties and support revenue over time.

For traders, the key is not to fall in love with any story, bullish or bearish. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your plan and your discipline.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” With TECH, that means mapping clear levels after this breakout, respecting the elevated valuation, and being ready for headline-driven spikes as the activist campaign and strategic review chatter develop. This is educational, research-focused analysis—not a buy or sell call—but TECH has all the ingredients to stay on serious traders’ radar in the weeks and months ahead.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks